Keyword: Allergan

allergan irvine

45. Ubrelvy

There are already three CGRP-aimed drugs for preventing migraine, but Allergan's Ubrelvy is the first oral drug for the acute treatment of migraines.
Jeuveau

1. Jeuveau

Unlike previous competitors from Galderma and Merz, Evolus' Jeuveau is "the first toxin that is really similar to Allergan’s Botox, a claim which is supported by a head-to-head study.”
allergan irvine

9. Rapastinel

Rapastinel, a depression drug that Allergan picked up via its $560 million acquisition of Naurex in 2015, hit the buffers after missing its objectives in no fewer than four pivotal trials this year and has now been abandoned.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.
allergan irvine

Allergan | Cenicriviroc

Allergan picked up its lead NASH program, cenicriviroc, in its 2016 acquisition of Tobira Therapeutics, just after it failed a phase 2b NASH study. With regulators’ support, Tobira retooled the endpoint for the phase 3 study, which Allergan is carrying forward.